Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View

Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View

Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related deaths and accounts for over eighty percent of primary liver cancers worldwide. Surgical resection and radiofrequency ablation in small tumors are included in the treatment options for HCC patients with good liv...

Full description

Bibliographic Details
Main Authors: Abdelrahim, M. (Author), Abdel-Wahab, N. (Author), Abudayyeh, A. (Author), Chang, J.C (Author), Diab, A. (Author), Esmail, A. (Author), Gaber, A.O (Author), Ghobrial, R.M (Author), Kaseb, A.O (Author), Murakami, N. (Author), Saharia, A. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
allograft rejection
CTLA-4 inhibitors
hepatocellular carcinoma
immune checkpoint inhibitors
immunotherapy
liver transplantation
PD-1 inhibitors
transplant oncology
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items